SAN FRANCISCO, Nov. 29, 2016 /PRNewswire/ -- Kindred
Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company
focused on saving and improving the lives of pets, today announced
that Emily Sundman, DVM, Clinical
Development Scientist for KindredBio, will present pivotal
effectiveness data for Zimeta™ (dipyrone injection) at the American
Association of Equine Practitioners (AAEP) Convention in
Orlando, FL on Tuesday, December 6, 2016 at 8:25 AM ET as part of the Internal Medicine
track. The presentation will be available at
http://kindredbio.com/investor-relations/events/ following the AAEP
presentation.
Zimeta is a pyrazolone anti-inflammatory drug with a unique
mechanism of action that is under development for the control of
pyrexia (fever) in horses. The application for Zimeta is currently
under review at the FDA Center for Veterinary Medicine (CVM).
Approval and launch of the drug is expected in 2017.
About Kindred Biosciences
Kindred Biosciences is a development-stage biopharmaceutical
company focused on saving and improving the lives of pets.
Its mission is to bring to pets the same kinds of safe and
effective medicines that human family members enjoy. The
Company's strategy is to identify compounds and targets that have
already demonstrated safety and efficacy in humans and to develop
therapeutics based on these validated compounds and targets for
dogs, cats and horses. The Company has a deep pipeline of
novel drugs and biologics in development across many therapeutic
classes.
For more information or to download the corporate presentation,
visit www.KindredBio.com/LearnMore. Stay connected with KindredBio
on Facebook at www.Facebook.com/KindredBio.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including, but not limited to,
statements regarding our expectations about the trials, regulatory
approval, manufacturing, distribution and commercialization of our
current and future product candidates, and statements regarding our
anticipated revenues, expenses, margins, profits and use of
cash.
These forward-looking statements are based on our current
expectations. These statements are not promises or guarantees, but
involve known and unknown risks, uncertainties and other important
factors that may cause our actual results to be materially
different from any future results expressed or implied by the
forward-looking statements. These risks include, but are not
limited to, the following: our limited operating history and
expectations of losses for the foreseeable future; the absence of
revenue from our product candidates for the foreseeable future; our
potential inability to obtain any necessary additional financing;
our substantial dependence on the success of our lead product
candidates, which may not be successfully commercialized even if
they are approved for marketing; the effect of competition; our
potential inability to obtain regulatory approval for our existing
or future product candidates; our dependence on third parties to
conduct some of our development activities; our dependence upon
third-party manufacturers for supplies of our product candidates;
uncertainties regarding the outcomes of trials regarding our
product candidates; our potential failure to attract and retain
senior management and key scientific personnel; uncertainty about
our ability to develop a satisfactory sales organization; our
significant costs of operating as a public company; our potential
inability to obtain patent protection and other intellectual
property protection for our product candidates; potential claims by
third parties alleging our infringement of their patents and other
intellectual property rights; our potential failure to comply with
regulatory requirements, which are subject to change on an ongoing
basis; the potential volatility of our stock price; and the
significant control over our business by our principal stockholders
and management.
For a further description of these risks and other risks that we
face, please see the risk factors described in our filings with the
U.S. Securities and Exchange Commission (the SEC), including the
risk factors discussed under the caption "Risk Factors" in our
Annual Report on Form 10-K and any subsequent updates that may be
contained in our Quarterly Reports on Form 10-Q filed with the SEC.
As a result of the risks described above and in our filings
with the SEC, actual results may differ materially from those
indicated by the forward-looking statements made in this press
release. Forward-looking statements contained in this press
release speak only as of the date of this press release and we
undertake no obligation to update or revise these statements,
except as may be required by law.
Contact
Russell
Radefeld
KindredBio
russell.radefeld@kindredbio.com
(650) 701-7904
Logo -
http://photos.prnewswire.com/prnh/20161023/431547LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/kindred-biosciences-to-present-zimeta-pivotal-data-at-the-62nd-annual-american-association-of-equine-practitioners-convention-300369386.html
SOURCE Kindred Biosciences, Inc.